A detailed history of Summit Global Investments transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Summit Global Investments holds 11,868 shares of REGN stock, worth $9.95 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares
11,868
Previous 9,673 22.69%
Holding current value
$9.95 Million
Previous $10.2 Million 22.71%
% of portfolio
0.8%
Previous 0.69%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$1024.09 - $1201.76 $2.25 Million - $2.64 Million
2,195 Added 22.69%
11,868 $12.5 Million
Q2 2024

Jul 22, 2024

SELL
$883.2 - $1071.19 $2.34 Million - $2.84 Million
-2,651 Reduced 21.51%
9,673 $10.2 Million
Q1 2024

Apr 29, 2024

SELL
$902.69 - $993.35 $3.53 Million - $3.89 Million
-3,915 Reduced 24.11%
12,324 $11.9 Million
Q4 2023

Feb 06, 2024

BUY
$775.18 - $881.7 $12.3 Million - $14 Million
15,931 Added 5172.4%
16,239 $14.3 Million
Q3 2023

Oct 13, 2023

BUY
$692.45 - $844.37 $5,539 - $6,754
8 Added 2.67%
308 $254,000
Q2 2023

Jul 18, 2023

BUY
$700.03 - $830.35 $210,009 - $249,105
300 New
300 $216,000
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $10.2 Million - $12.6 Million
-18,835 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$574.03 - $680.96 $1.46 Million - $1.73 Million
2,535 Added 15.55%
18,835 $11.4 Million
Q2 2021

Jan 28, 2022

BUY
$472.8 - $558.54 $337,106 - $398,239
713 Added 4.57%
16,300 $9.09 Million
Q1 2021

Jan 27, 2022

BUY
$446.73 - $548.2 $6.6 Million - $8.1 Million
14,779 Added 1829.08%
15,587 $7.38 Million
Q4 2020

Feb 11, 2021

BUY
$478.3 - $607.98 $99,008 - $125,851
207 Added 34.44%
808 $390,000
Q3 2020

Nov 16, 2020

BUY
$544.75 - $658.21 $327,394 - $395,584
601 New
601 $336,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $89.8B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Summit Global Investments Portfolio

Follow Summit Global Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.